Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and children over the age of 6.
Unipharm’s Atomoxetine Tablets are all scored, enabling a wider range of dosing for ADHD treatment in comparison with Strattera Capsules, making this a value-added generic product.
Unipharm’s generic Atomoxetine Tablets have been manufactured and marketed in Israel since 2018. This Added Value Product’s Dossier includes a new EU bioequivalence study compared to the EU Reference Listed Drug, Strattera.
